Credit: EASL via Linkedin
June 7, 2024 11:21 AM EDT
R&D

Ali­gos, Ar­bu­tus and oth­ers tout ear­ly he­pati­tis ef­fi­ca­cy da­ta at #EASL24

Katherine Lewin

News Reporter

Max Bayer

Pharma Reporter

At this year’s EASL In­ter­na­tion­al Liv­er Con­gress, Vir took cen­ter stage Wednes­day to re­port ear­ly Phase 2 da­ta for its he­pati­tis D …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times